PSEN1
Pathway Diagram
Mermaid diagram (expand to render)
Overview
PSEN1 (Presenilin 1) is a transmembrane protein encoded by the PSEN1 gene located on chromosome 14q24.3. This protein serves as a catalytic component of the γ-secretase complex, a critical enzyme responsible for the intramembranous cleavage of numerous substrates, most notably the amyloid precursor protein (APP). PSEN1 mutations represent one of the most common genetic causes of early-onset Alzheimer's disease (EOAD), with over 200 pathogenic variants identified to date. The protein's essential role in APP processing and subsequent amyloid-β (Aβ) generation has made PSEN1 a central focus of neurodegeneration research for three decades.
Function/Biology
PSEN1 functions as the catalytic subunit within the γ-secretase protease complex, which also includes nicastrin (NCT), anterior pharynx defective-1a (APH1a), and presenilin enhancer 2 (PEN2). This 200-kDa protein complex performs proteolytic cleavage of transmembrane domains of various substrates within the lipid bilayer environment. PSEN1 contains nine transmembrane domains, with two conserved aspartate residues (D257 and D385 in human PSEN1) serving as the catalytic dyad necessary for protease activity.
The primary biological function involves sequential processing of APP: first by α-secretase or β-secretase to generate a C-terminal fragment, which is subsequently cleaved by γ-secretase in an intramembranous manner. This produces Aβ peptides and the APP intracellular domain (AICD). Beyond APP, PSEN1-containing γ-secretase cleaves over 100 additional substrates, including Notch signaling proteins, EphB2 receptor, p75 neurotrophin receptor, and β-catenin, reflecting its broader importance in cellular signaling and homeostasis.
Role in Neurodegeneration
PSEN1 mutations account for approximately 30-50% of familial Alzheimer's disease cases with an autosomal dominant inheritance pattern. Pathogenic variants typically result in increased production of amyloidogenic Aβ42, the predominant form deposited in amyloid plaques, or alterations in the Aβ42/Aβ40 ratio. This shift toward more aggregation-prone Aβ42 promotes formation of neurotoxic oligomers and ultimately dense amyloid deposits in brain tissue.
Beyond APP processing, PSEN1 mutations likely impair γ-secretase activity toward other substrates, disrupting Notch signaling, calcium homeostasis, and synaptic plasticity. The protein has been implicated in autophagy regulation, mitochondrial dysfunction, endoplasmic reticulum (ER) stress, and oxidative stress—all hallmarks of neurodegeneration. Loss-of-function mechanisms appear equally important alongside gain-of-function effects, creating complex pathogenic scenarios.
Molecular Mechanisms
The molecular basis for PSEN1-related pathology involves several converging mechanisms. Loss of catalytic function of γ-secretase due to certain mutations impairs cleavage of protective substrates, reducing production of AICD and impairing calcium signaling. Conversely, many PSEN1 mutations increase the enzymatic production of pathogenic Aβ42 while maintaining relatively normal processing of other substrates.
PSEN1 mutations compromise intracellular calcium regulation by disrupting inositol 1,4,5-trisphosphate receptor (IP3R) and ryanodine receptor (RyR) function, leading to enhanced calcium release from the ER and increased vulnerability to excitotoxic stress. Mutations also elevate reactive oxygen species (ROS) production and impair mitochondrial calcium buffering capacity, amplifying neuronal dysfunction and apoptosis.
Additionally, PSEN1 mutations alter APP trafficking and subcellular localization, affecting the sites and kinetics of proteolytic processing. They disrupt lipid raft organization, essential for efficient APP cleavage and Notch signaling coordination.
Clinical/Research Significance
PSEN1 mutations typically cause symptom onset between ages 30-60 years, with rapidly progressive cognitive decline and pronounced amyloid pathology. Genetic testing for PSEN1 variants is standard diagnostic practice in families with EOAD. Individuals carrying pathogenic PSEN1 mutations show remarkably high penetrance, approaching 100% by age 80.
PSEN1 has been instrumental in validating the amyloid cascade hypothesis of Alzheimer's disease, driving development of γ-secretase inhibitors and modulators as therapeutic strategies. However, clinical translation has proven challenging due to off-target effects and complications from reduced processing of other substrates.
- PSEN2: Presenilin 2, a paralogous protein also causing familial Alzheimer's disease
- APP: Amyloid precursor protein, primary γ-secretase substrate
- APOE4: Apolipoprotein E ε4, additional Alzheimer's disease risk factor